Adventrx Pharmaceuticals Set Back by FDA, La Jolla Pharmaceutical Can’t Cure Shareholder Apathy, Regulus Signs Another Deal With Glaxo, & More San Diego Life Sciences News

3/4/10Follow @bvbigelow

(Page 2 of 2)

FDA’s comments are specific to a promotional brochure that no longer in use.

—Avalon Ventures partner and aFraxis CEO Jay Lichter explained how the early stage biotech saved millions by working with Torrey Pines Investment, a San Diego life sciences investment firm that owns a full-service contract research organization near Moscow. AFraxis is developing a drug therapy for treating Fragile X, a genetic defect that causes autism and related disabilities.

—GlaxoSmithKline has pulled out its checkbook a second time for Regulus, the Carlsbad, CA-based spinoff of nearby Isis Pharmaceuticals and Cambridge, MA-based Alnylam Pharmaceuticals. Regulus says Glaxo could pay as much as $150 million in their second collaboration, which is aimed at developing a microRNA drug for hepatitis C.

Several life sciences startups in the San Diego area have received funding in recent weeks. Auspex Pharmaceuticals raised $3 million, Aethlon Medical raised $600,000, and Tocagen got $3 million.

—What are the organizations in San Diego that are supporting innovation in biotech and medical devices? What are the corporate venture funds that invest in biomedical startups? Xconomy has the answers ready for you in the X Lists, a new resource where we list the resources available in San Diego according to the stages in a startup’s development: Start, Fund, Network, Work & Grow, and Analyze.


Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @bvbigelow

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.